Adoptively transferred tumor-specific T cells expanded ex vivo using HSV amplicons encoding 4-1BBL show increased anti-tumor activity in vivo
Maria Jure‐Kunkel(Genmab (United States)), L J Hefta(Bristol-Myers Squibb (United States)), Ralph Abraham(Bristol-Myers Squibb (United States)), Praveen Balimane(Bristol-Myers Squibb (United States)), Sandra A. Calarota(University of Pennsylvania), Emel Girit(Bristol-Myers Squibb (United States)), Karen Price(Purchase College), David Weiner(Bristol-Myers Squibb (United States))
Cancer Research
April 15, 2006
Cited by 1
Related Papers
Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties
|American Journal of Transplantation|2005|714
Standardization of cytokine flow cytometry assays
|BMC Immunology|2005|240
Cancer Drug Discovery and Development
|Humana Press eBooks|2003|194
Development of a Chimeric Anti-CD40 Monoclonal Antibody That Synergizes with LEA29Y to Prolong Islet Allograft Survival
|The Journal of Immunology|2005|183
Pharmacokinetic Drug Interactions Involving 17??-Ethinylestradiol
|Clinical Pharmacokinetics|2007|174